share_log

Chimerix | 10-Q: Q3 2024 Earnings Report

Chimerix | 10-Q: Q3 2024 Earnings Report

Chimerix | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/07 04:33

Moomoo AI 已提取核心訊息

Chimerix reported Q3 2024 revenues of $26,000 and a net loss of $22.9 million ($0.26 per share), compared to revenues of $11,000 and a net loss of $24.0 million ($0.27 per share) in Q3 2023. Research and development expenses increased to $19.6 million from $17.4 million YoY, primarily due to costs related to the Phase 3 ACTION study of dordaviprone and manufacturing expenses.The company continues to advance its Phase 3 ACTION trial evaluating dordaviprone for H3 K27M-mutant diffuse glioma, with over 145 sites now enrolling patients across 15 countries. A recent Independent Data Monitoring Committee safety review recommended the study continue as planned. Management expects interim overall survival data to be available in Q3 2025.As of September 30, 2024, Chimerix maintained a strong financial position with $152.4 million in capital available to fund operations. The company is also pursuing potential approval pathways in Australia, having received Provisional Determination approval in August 2024 and Orphan Drug Designation in September 2024. The company continues development of second-generation compound ONC206, with dose escalation studies expected to complete in 2024.
Chimerix reported Q3 2024 revenues of $26,000 and a net loss of $22.9 million ($0.26 per share), compared to revenues of $11,000 and a net loss of $24.0 million ($0.27 per share) in Q3 2023. Research and development expenses increased to $19.6 million from $17.4 million YoY, primarily due to costs related to the Phase 3 ACTION study of dordaviprone and manufacturing expenses.The company continues to advance its Phase 3 ACTION trial evaluating dordaviprone for H3 K27M-mutant diffuse glioma, with over 145 sites now enrolling patients across 15 countries. A recent Independent Data Monitoring Committee safety review recommended the study continue as planned. Management expects interim overall survival data to be available in Q3 2025.As of September 30, 2024, Chimerix maintained a strong financial position with $152.4 million in capital available to fund operations. The company is also pursuing potential approval pathways in Australia, having received Provisional Determination approval in August 2024 and Orphan Drug Designation in September 2024. The company continues development of second-generation compound ONC206, with dose escalation studies expected to complete in 2024.
Chimerix公佈2024年第三季度收入爲26000美元，淨虧損爲2290萬 ($0.26每股)，相比之下，2023年第三季度收入爲11000美元，淨虧損爲2400萬 ($0.27每股)。研發支出同比增加至1960萬，去年爲1740萬，主要是由於與dordaviprone的第三階段ACTION研究及製造業費用相關。該公司繼續推進評估dordaviprone用於H3 K2700萬.mutant瀰漫性膠質瘤的第三階段ACTION試驗，現已有超過145個地點在15個國家招募患者。最近，獨立數據監測委員會的安全審查建議繼續按計劃進行該研究。管理層預計在2025年第三季度將提供中期總體生存數據。截至2...展開全部
Chimerix公佈2024年第三季度收入爲26000美元，淨虧損爲2290萬 ($0.26每股)，相比之下，2023年第三季度收入爲11000美元，淨虧損爲2400萬 ($0.27每股)。研發支出同比增加至1960萬，去年爲1740萬，主要是由於與dordaviprone的第三階段ACTION研究及製造業費用相關。該公司繼續推進評估dordaviprone用於H3 K2700萬.mutant瀰漫性膠質瘤的第三階段ACTION試驗，現已有超過145個地點在15個國家招募患者。最近，獨立數據監測委員會的安全審查建議繼續按計劃進行該研究。管理層預計在2025年第三季度將提供中期總體生存數據。截至2024年9月30日，Chimerix保持強勁的財務狀況，擁有15240萬的資金可用於運營。該公司還在澳洲尋求潛在的批准途徑，於2024年8月獲得暫時決定批准，並於2024年9月獲得孤兒藥認定。該公司繼續開發第二代Compound ONC206，預計在2024年完成劑量遞增研究。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    美聯儲暫停降息，你如何調整持倉？
    美聯儲宣布基準利率維持在4.25%—4.50%不變，符合市場預期。你會如何配置資產？ 展开
    FOMC新聞發佈會，2025年1月29日